(firstQuint)A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects.

 This study represents the administration of dipeptidyl peptidase 4 (DPP4) inhibitor DBPR108 to humans to evaluate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties following multiple oral doses in healthy subjects.

 DPP4 is a validated drug target for the treatment of human type 2 diabetes.

 Objectives of the study will be to assess the safety and tolerability, PKs and PDs of DBPR108 at steady state after administration of multiple oral doses to healthy male subjects.

.

 A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects@highlight

The study is being performed to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of multiple oral doses of DBPR108 in healthy male subjects.

